A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

What this study is about

This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks

Who can join (things the study team will check)

✅ You may be able to join if…

• Male or female (sex assigned at birth, inclusive of all gender identities).
• Age 18 years or above at the time of signing the informed consent.
• BMI≥ 35.0 kg/m\^2.
• Participants without T2D: No history of T2D and HbA1c < 6.5% (48 millimoles per mole (mmol/mol)) Participants with T2D: A history of T2D and HbA1c < 10% (< 86 mmol/mol). If a participant without a history of diabetes during the screening period receives an HbA1c result of 6.5% (48 mmol/mol) or higher, the investigator or the participant's healthcare provider must confirm the diagnosis of type 2 diabetes before the participant is randomised.

🚫 You may not be able to join if…

• A self-reported change in body weight > 5% within 90 days before screening, irrespective of medical records.
• Use of any glucagon-like-peptide-1 receptor agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin analogues, including medication with amylin activity, within 6 months before screening.

Where this trial is running

• Uni of Alabama at Birmingham, Birmingham, Alabama, United States
• Cahaba Research, Pelham, Alabama, United States
• Elligo Health Research Inc, Gilbert, Arizona, United States
• Velocity Clinical Research-Phoenix, Phoenix, Arizona, United States
• Arkansas Clinical Research, Little Rock, Arkansas, United States
• Woodland Int. Research Group, Little Rock, Arkansas, United States
• Headlands Research California, LLC, Escondido, California, United States
• Neighborhood Healthcare, Escondido, California, United States
• Diabetes & Endocrine Specialists - La Mesa, La Mesa, California, United States
• Clinical Trials Research_Sacramento, Lincoln, California, United States
• Loma Linda University Faculty Medical Clinics, Loma Linda, California, United States
• Pacific Clinical Studies, Los Alamitos, California, United States

+ 291 more sites.

Who to contact

Novo Nordisk · (+1) 866-867-7178 · clinicaltrials@novonordisk.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07564414.